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Abstract
Particulate matter (PM), a component of air pollution, has been shown to enhance allergen-
mediated airway hypersensitivity and inflammation. Surprisingly, exposure to PM during the 
sensitization to allergen is sufficient to produce immunological changes that result in heightened 
inflammatory effects upon future allergen exposures (challenge) in the absence of PM. This 
suggests that PM has the ability to modulate the allergic immune response, thereby acting as an 
adjuvant by enhancing the immunological memory formed during the adaptive immune response; 
however, the mechanisms through which this occurs remain elusive. Establishing a reproducible 
animal model to study the PM-mediated immunotoxicological effects that enhance allergy, may 
provide insights to understand how air pollution activates the immune system and thereby 
modulates the pathophysiology of asthma. The protocol detailed below can be used to study 
various characteristics of air pollution, such as PM size, source, or chemical composition, to help 
elucidate how such features may affect the allergic response in a mouse model of asthma. Using a 
BALB/c model of acute exposure (14 days) mice are first sensitized with allergen and PM then 
subsequently challenged with allergen only. The endpoints of this protocol include the assessment 
of inflammation via cells recovered from broncho-alveolar lavage (BAL), histopathological 
analysis, gene expression profiles, and protein quantification of inflammatory markers.
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Allergic asthma is characterized by airway inflammation and hypersensitivity in individuals 
that become sensitized to innocuous allergens. Common human allergens that trigger 
asthmatic attacks are proteins derived from sources such as pollen, dust mites, animal 
dander, and mold spores. Allergic asthma develops when the immune system fails to develop 
tolerance towards an inhaled protein antigen and subsequently develops immunological 
memory towards that antigen. Primarily, this occurs through antigen-specific IgE antibodies 
and T helper type 2 (Th2) immune responses. Upon subsequent encounters with the antigen 
(i.e., allergen), IgE-allergen complex binding to FcεRI-receptors on mast cells and basophils 
triggers these cells to become activated and release inflammatory mediators, such as 
cytokines and chemokines as well as broncho-constricting mediators, such as histamine, 
leukotrienes, and prostaglandins. Mast cell- and eosinophil-mediated cytokine release 
induces inflammation by recruiting additional immune cells into the airways as well as 
reinforcing Th2-cell differentiation. Collectively, these events elicit coughing, wheezing, and 
shortness of breath commonly observed during asthmatic attacks.
The immunotoxicity that develops from exposure to particulate matter may manifest itself as 
hyperactivation and/or misregulation of the immune response. Clinically, this may 
predispose individuals to disease or enhance morbidity and mortality of existing conditions, 
such as asthma, COPD, pneumonia, and cardiovascular disease (Anderson et al., 2012; 
Samet et al., 2000). Interestingly, the inflammatory range of PM may extend beyond the 
lung, the organ of primary deposition. In recent years PM exposure has been linked to 
autism, ischemic stroke, schizophrenia, and cancer; however, these relationships are 
correlative and casual relationships have yet to be established (Kalkbrenner et al., 2015; 
Pedersen et al., 2004; Turner et al., 2011; Wellenius et al., 2012).
The incidence of asthma and allergic diseases has steadily risen in the past few decades 
(Moorman et al., 2012). With respect to asthma, epidemiological studies have demonstrated 
a higher incidence of disease in areas of high air pollution, particularly traffic related 
pollution (Bowatte et al., 2015). This relationship has been extensively modeled in animals, 
primarily rodents, where either single particles, laboratory generated particles, or ambient 
particles are given in conjunction with an allergen to study how PM modulates the allergic 
immune response. Nonetheless, the immuno-toxicological mechanisms by which PM 
modulates the immune system still remain unclear. It should be noted that PM mixtures are 
highly complex in chemical composition as they differ with source and thus, differentially 
affect the immune mediated inflammatory response with some fractions of PM enhancing 
the allergic response and others producing no change (Carosino et al., 2015).
The protocol described can be used to investigate the in-vivo immunotoxicological 
mechanisms through which PM exacerbates the pulmonary allergic immune response. A key 
component of this model is the ability to assess the potential toxicity of PM that has been 
characterized by particle size (PM10, PM2.5, PM0.1), ambient source (urban, rural, vehicular 
emissions, etc.), predominant composition (major/trace metals, inorganic ions, polyaromatic 
hydrocarbons, organic compounds, or elemental/organic carbons), or time collection points 
(seasonal, day/night). The Basic Protocol describes the sensitization of mice (days 1, 3 and 
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5) with either allergen alone or the combination of allergen with PM. The appropriate time is 
allotted for the formation of immunological memory (days 6-11), and mice are challenged 
(days 12-14) with allergen alone to induce an allergic response. Exposure to PM during 
allergen sensitization is sufficient to alter immunological memory formation as the 
subsequent allergen challenge (in the absence of PM) enhances the inflammatory response 
compared to mice only sensitized and challenged with allergen. This protocol, therefore, 
allows the investigator to assess how various types of PM modulate the formation of 
immunological memory against the allergen.
To characterize PM-mediated inflammatory changes during the allergic response this 
protocol outlines various assays including broncho-alveolar lavage (BAL) to assess airway 
inflammation via recovered immune cells, gene expression analysis via qPCR to determine 
upregulation of genes that mediate inflammation, and collection of total lung protein to 
perform enzyme-linked immunosorbent assay (ELISA) or other protein based assays to 
confirm gene expression changes. Furthermore, the reader is referred to a Support Protocol 
(Zeller, 2001) for histopathological analysis to determine pulmonary inflammation and 
assessment of PM immunotoxicity.
BASIC PROTOCOL
INTRANASAL SENSITIZATION (ALLERGEN AND PARTICULATE MATTER) AND 
CHALLENGE (ALLERGEN ALONE)
The mouse model used for this protocol is the BALB/c mouse, a strain that is Th2-dominant 
as opposed to the C57BL6 mouse that is Th1-dominant (Nials and Uddin, 2008). BALB/c 
mice develop the classical characteristics of an allergic response, including Th2-immune 
responses, allergen-specific IgE, eosinophilic airway inflammation, and airway 
hyperresponsiveness (AHR). An investigator may choose to use a different mouse strain than 
the BALB/c to accommodate their scientific question, but note that the allergic response may 
differ.
Mice are intranasally sensitized with allergen on days 1, 3 and 5. This is followed by a seven 
day rest period to allow for the formation of the adaptive immune response towards the 
allergen. Mice are intranasally challenged with allergen on days 12, 13, and 14 to elicit an 
allergic inflammatory response. Finally, on day 15, mice are euthanized to collect BAL and 
lung tissue for assessment of inflammation. Proper controls should be utilized for this study 
and should include a control group (administration of the delivery vehicle-only for 
sensitization and challenge periods) and a PM control treatment group (administration of 
PM-only during the sensitization period and delivery vehicle-only for the challenge period).
Mice are sensitized using either ovalbumin (OVA) or house dust mite (HDM). Based on 
work from our lab, we have shown that ambient PM enhances both OVA and HDM allergic 
responses (unpublished data) (Carosino et al., 2015). OVA has been used extensively in 
rodent models of human asthma. Specifically in BALB/c mice OVA elicits many of the 
features of human asthma although the limitations are modest pulmonary inflammation and 
mild AHR. Although OVA can cause occupational asthma in individuals working in egg 
processing facilities, house dust mite is a more humanly relevant allergen and is one of the 
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most common allergens to trigger asthma. Similar to OVA, HDM mouse models of human 
asthma also elicit many of the features commonly seen in human asthma. Unlike OVA, 
which is a single protein, commercially available HDM allergen (Greer® Laboratories) is 
composed of whole ground dust mites (D. farinae or D. pteronyssinus) that contain a much 
more diverse array of allergens and pattern recognition receptor ligands (proteases, 
lipopolysaccharides/endotoxin, β-glucans, and chitin) (Gregory and Lloyd, 2011). The use 
of whole dust mites in HDM allergen preparation results in an allergen rich in endotoxin and 
more closely mimics natural human exposure. Additionally, endotoxin in HDM may have 
differential inflammatory effects via Toll-like receptors, OVA on the contrary is usually 
relatively low in endotoxin. As a result of the spectrum of allergens in HDM and endotoxin 
contamination, HDM produces a more robust inflammatory response in the lung compared 
to OVA when both are administered intranasally (sensitization and challenge) on an equal 
mass basis (unpublished data). Since endotoxin enhances inflammation, the amount of 
endotoxin should be screened with a limulous amoebocyte lysate test (discussed later). OVA 
sensitization may be performed via intraperitoneal (i.p.) administration with alum and 
challenged by OVA inhalation to produce more robust pulmonary inflammation; however, 
we have had inconclusive results using this method as the robust allergic response masks the 
inflammatory PM-mediates effects. For this reason, and for the fact that i.p. exposure to 
OVA is not a normal method of allergy development in humans (i.e., systemic immune 
responses differ from mucosal immune responses), we recommend the administration of 
HDM intranasally as it is a humanly relevant allergen that produces substantial 
inflammatory effects that resemble many of the underlying features of human asthma.
The investigator may choose which source of PM to utilize for their experiment. 
Commercially available PM is available through the National Institute of Standards and 
Technology Standard Reference Materials (http://www.nist.gov/srm), with many sources 
having a chemical characterization profile. Alternatively, ambient PM may be collected by 
the investigator. We refer the reader to various publications that outline the collection of 
ambient PM (Ayres et al., 2008; Kulkarni et al., 2011). Furthermore, we strongly emphasize 
the need to sonicate PM immediately before administration, as once PM is resuspended in 
solution particle agglomeration occurs rapidly and has the potential to diminish the 
inflammatory response.
NOTE: All protocols using live animals must first be reviewed and approved by an 
Institutional Animal Care and Use Committee (IACUC). Researchers must abide by IACUC 
guidelines when handling laboratory animals.
NOTE: The investigator should consult the manufacturer’s instruction manual for specific 
information regarding the operation of specialized instrumentation, equipment, and software 
as well as appropriate protocol procedures for assays.
Materials—Mice
Allergen (Ovalbumin or House Dust Mite Allergen, Greer® Laboratories)
Particulate matter
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Ultrasonic cleaner water bath
Delivery vehicle: saline, phosphate buffered saline (PBS), or Hank’s balanced salt solution 
(HBSS); use the same delivery vehicle for all further support protocols
Veterinary anesthesia machine with anesthesia induction chamber
Isoflurane
Timer
20μL, 200μL, and 1000μL pipettes with appropriate tips
Balance for weighing mice
Data sheets for recording animal weights and dosing schedule
Prepare Allergen—
1. Dissolve 1 mg/mL OVA (Grade V; Sigma) or 1 mg/mL HDM allergen 
(Greer Laboratories) into a sterile and endotoxin-free delivery vehicle 
(saline, PBS, or HBSS). Gently vortex this “stock solution” and then allow 
it to dissolve for 1 hr or overnight at 4°C. The solution may be dispensed 
into aliquots or stored as is at −20°C or −80°C (avoid freeze-thaw cycles).
A 25μL dose/per mouse/day at a concentration of 1mg/mL 
allergen solution will deliver 25 μg of allergen. Common doses 
used in allergy models in the literature for both OVA and HDM 
range between 10ug to100ug/per mouse/day. The user may wish 
to change the dose based on their scientific investigation by re-
calculating the “stock solution” to achieve the desired allergen 
mass while maintaining a dosing volume of 25-30μL as this is an 
optimal volume to deliver intranasally to mice between 6-8 weeks 
of age. Avoid exceeding an intranasal delivery volume greater 
than 50μL.
Prepare Particulate Matter—
2. Dissolve 1 mg/mL of PM into the sterile, endotoxin-free delivery vehicle 
solution to create a stock solution.
3. Place the glass vial or microcentrifuge containing the PM solution in an 
ultrasonic cleaner water bath at 60 sonics/min for 10-15 min to eliminate 
particle agglomerates.
4. After sonication, immediately aliquot the solution into microcentrifuge tubes 
for each day of dosing. Freeze the microcentrifuge tubes that will not be used 
that day at −20°C.
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Sonication is an essential step that is necessary to prevent PM 
agglomeration prior to dosing. Failing to sonicate particles each day 
prior to dosing can result in no change or even a suppression of the 
allergic response.
5. On day 1, administer the PM immediately after sonication as particle 
agglomeration can occur as quickly as 30 min.
Typically, three aliquots (one for each day of dosing) are sufficient for 
dosing. However when working with a large number of animals, more 
than 1 aliquot per day may need to be prepared if dosing takes longer 
than 30 min. The aliquots may have to be sonicated in a staggered 
time fashion to prevent particle agglomeration.
6. On days 3 and 5, thaw the frozen PM aliquots. Aliquots that are thawed each 
day for dosing will need to be sonicated 10-15 min to eliminate particle 
agglomeration.
Intranasal Sensitization with Particulate Matter and Allergen (Days 1, 3, and 5)
—Animals will be dosed in two separate rounds. The first round will consist of anesthetizing 
and administering the PM dose to the appropriate treatment groups (PM-only and allergen
+PM groups). The allergen+PM group will be allowed a short recovery period. The second 
round consists of anesthetizing and administering the delivery vehicle or allergen to the 
appropriate groups (delivery vehicle control, allergen, and allergen+PM groups). Separating 
the delivery of PM and allergen in the allergen+PM group ensures that the PM does not bind 
or agglomerate with the allergen.
7. Mice should be randomly divided into each control/treatment group and tail 
marked.
8. A veterinary anesthetic machine is used to sedate mice. The system should 
contain an oxygen tank that feeds into the anesthetic vaporizer, followed by a 
flowmeter that feeds the vaporized isoflurane into an anesthesia induction 
chamber. Finally an activated charcoal adsorption filter is attached to the 
anesthetic chamber to collect isoflurane fumes.
9. Ensure that the anesthetic vaporizer reservoir is filled with isoflurane and is 
set to “On” with an output of 2%. Open the oxygen tank pressure valve and set 
the flow rate to 1 L/min. Allow 2-3 min for the anesthesia induction chamber 
to become saturated with isoflurane.
10. Begin with the PM administration (first round) for the appropriate 
treatment groups. Ensure that the PM is sonicated immediately before its 
administration to animals (see Steps 4-5).
11. Place a mouse into the anesthesia induction chamber, closing the lid once 
the animal is inside, and begin the timer. Mice will become unconscious within 
1-1.5 min. Allow the animal to remain in the chamber for a total of 3-5 min, 
this will allow the mouse to undergo a deep pane of anesthesia that will allow 
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the researcher to have the appropriate time to administer the dose intranasally 
before the animal regains consciousness.
The amount of time the mouse should be left in the anesthesia 
induction chamber depends on weight and age, with older and heavier 
mice taking longer time to become unconscious. Begin with 3 min 
and increase the time as necessary.
12. Prior to removing the animal from the anesthetic chamber, pre-load the 
pipette tip with 15μL of PM solution.
13. Remove the unconscious mouse from the chamber and quickly administer 
the PM dose intranasally. Hold the mouse in the non-dominant hand and using 
the dominant hand carefully and quickly bring the pipette tip 1-2mm above the 
nares of the mouse, and in a slow drop-wise manner, alternate administering 
the drops between each nare. As the animal naturally inspires, the solution will 
be inhaled into the lungs.
The animal will begin to regain partial consciousness within 15-30 sec 
awake. Therefore, it is important to administer the dose quickly, 
ideally within 5 sec.
14. Once the dose is administered, return the animal to its cage, preferably in a 
position that does not allow the dose to reflux into the trachea/nares. If time 
suffices, the animal can be weighed while under anesthesia. Alternatively, the 
mice can be weighed prior to dosing. The animal will regain full consciousness 
within 1-2 min after being removed from the chamber.
15. Reset the timer and repeat the procedure with the remaining mice (Steps 
11-14).
16. Administer the delivery vehicle or allergen dose intranasally (second 
round) to the appropriate treatment groups by repeating Steps 11-15 with the 
expectation of using 25μL of delivery vehicle or allergen solution, respectively. 
For animals that receive the combination of allergen and PM, allow the animals 
to recover at least 15 min after the isoflurane-induced anesthesia before 
animals are sedated again for allergen administration.
17. Keep a record of the dosed animals or notes if issues arise during the 
procedure.
Intranasal Challenge with Allergen (Days 12-14)—
18. Repeat steps 8-17 (with the exception of not administering PM) using 
delivery vehicle or allergen-only for intranasal administration on days 12-14. 
During the challenge period, mice sensitized with PM only will receive the 
delivery vehicle and mice sensitized with the allergen+PM combination will 
receive allergen-only (i.e., no PM is administered during the challenge period).
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Necropsy and Tissue Collection—Necropsy occurs 24 hr after the final challenge. 
Mice are euthanized and BAL and lung tissue are collected to assess pulmonary 
inflammation. The investigator may wish to collect various tissues beyond those outlined in 
this protocol if systemic PM effects are being assessed or suspected. Ideally, a minimum of 3 
people are recommended to perform the necropsy in a day since SUPPORT PROTOCOL 1: 
Assessment of broncho-alveolar lavage fluid for pulmonary inflammatory cellular profiles 
will need to be performed on the same day as necropsy.
Materials—Pentobarbital sodium diluted in sterile saline to 65mg/mL
Balance for weighing mice
Absorbent paper (inscribe with animal ID numbers)
Surgical dissecting scissors (blunt)
Forceps (serrated, curved tip, and blunt)
Gauze
Cotton swabs
1mL syringe (optional for cardiac puncture) with 21-gauge hypodermic needle
EDTA coated tubes (optional for cardiac puncture; BD Microtainer®)
Surgical hemostats (serrated and non-serrated)
Braided silk suture (USP sizes 1 and 2-0)
Razor blade
Cannula (21-guage, 1”, blunt end for tracheal cannulation)
1mL syringe (for broncho-alveolar lavage)
Sterile saline, PBS, or HBSS (same as delivery vehicle; for broncho-alveolar lavage)
5mL polystyrene round bottom tubes (BD Falcon™, Fisher Scientific)
Container with ice
Reservoir with liquid nitrogen
Cryogenic tubes (Nunc, Thermo Scientific™)
RNAlater Solution© (optional; Ambion)
Weight boats
4% paraformaldehyde made in PBS
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20mL glass scintillation vials for storing fixed lungs (Sigma-Aldrich)
Data sheets for project date, treatment, animal ID numbers, anesthetic amounts, BAL 
volume recovery, and lung fixation time
Biohazard disposal bag for animals
Collection of Broncho-alveolar Lavage Fluid and Blood (Optional)—
1. Inject the mouse with 0.3mL of the 65mg/mL pentobarbital solution i.p. 
and place the animal back in its cage. Once the mouse is incapacitated (1-2 
min), remove it from its cage and weigh it.
2. Position the mouse in a supine position onto a 6”×9” absorbent paper. 
Stretch and tape all four legs and tail onto the paper.
3. Ensure the mouse has been euthanized by lightly pinching the toes; there 
should be no reflex.
4. Use surgical dissecting scissors to create an incision on the skin from the 
abdomen up to the throat.
5. With the non-dominant hand, use tweezers to pull the xiphoid process up, 
and with the dominant hand, use the scissors to slowly cut up the sternum 
to open the thoracic cavity. Be specifically careful not to puncture the 
lungs (begin with small incisions, the lungs will quickly retract once the 
cavity is punctured).
6. Perform cardiac puncture if blood will be collected and place it in EDTA 
coated tubes.
To process and analyze plasma, see section ASSESSMENT OF 
PLASMA IgE.
7. Secure the diaphragm with a hemostat. Pull the diaphragm downward to 
expose the thoracic cavity.
8. Using two tweezers, separate the muscles/fat/connective tissue 
surrounding the trachea. Once the trachea is isolated, place a 3” suture 
(USP size 1) underneath the trachea (Fig. 1).
9. On the anterior side of the trachea, make a 1-2 mm incision above the 
suture using a razor blade being careful not to severe the trachea as it will 
retract into the thoracic cavity. Insert a 21-guage blunt-end cannula into 
the trachea and tie the suture tightly to secure the cannula to the trachea 
(Fig. 1).
10. Use a 1mL syringe loaded with 0.6 mL sterile saline, PBS, or HBSS to 
perform whole lung lavage. Attach the syringe onto the cannula and 
slowly instill the solution; the lungs will begin to expand in the thoracic 
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cavity. Once all fluid has been instilled, recover the fluid by slowly 
drawing the fluid out of the lungs. Without removing the syringe from the 
cannula, instill and recover the lavage 2 more times for a total of 3 
instillations and 3 recoveries using the original 0.6mL solution. After the 
final recovery, remove the syringe from the cannula and place the lavage 
fluid in a 5mL round bottom tube (keep on ice).
To process broncho-alveolar lavage fluid, refer to section 
ASSESSMENT OF BRONCHO-ALVEOLAR LAVAGE FLUID 
FOR PULMONARY INFLAMMATORY CELLULAR 
PROFILES.
It is unlikely to recover the same volume of solution instilled in 
the lung. When removing the fluid from the lungs, stop pulling 
on the syringe when there is resistance in the syringe plunger as 
pulling on the plunger beyond this point may lead to rupturing of 
the lungs.
Optional: Using a non-serrated hemostat, clamp the left primary 
bronchus prior to broncho-alveolar lavage. This will leave the left 
lung undisturbed for a more accurate assessment of histology. 
Use half the volume for lavage (0.3mL). The lavaged right lung 
lobes can still be used for protein assays, gene expression 
analysis, or other assays to assess inflammation.
Collection of Lung Tissue—
11. Using a suture, tie the right lung where the primary right bronchus exits off 
the trachea (if the left lung was clamped during lavage, remove the hemostat). 
Using curved tweezers, grab a 3” suture. Carefully guide the tweezers in the 
closed position, holding the suture beneath the lungs in a diagonal direction 
beginning at the bottom right of the thoracic cavity and exiting on the top left 
of the thoracic cavity. Open the tweezer slightly and grasp the small suture 
with a second set of tweezers. Carefully pull back the first set of tweezers back 
down beneath the lungs while being careful not to puncture the lungs. Tie the 
suture tightly to isolate the right lung lobes (Fig. 2).
12. Cut the cranial, middle, caudal, and accessory lobes and place them in the 
appropriate cryovials.
For RNA isolation it is essential that the lung lobe is immediately 
flash frozen in liquid nitrogen followed by storage at -80°C to prevent 
enzymatic degradation of RNA. Alternatively, the lung lobe may be 
infused with RNAlater Solution© immediately after being cut by 
using a dissecting microscope to locate the bronchus and injecting 
0.1-0.2mL RNAlater Solution© with a 1mL syringe attached to a 
blunt ended cannula.
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To process one of the right lung lobes for gene expression analysis, 
refer to section ASSESSMENT OF PULMONARY 
INFLAMMATION VIA GENE EXPRESSION.
To process one of the right lung lobes for protein/ELISA based 
assays, refer to section ASSESSMENT OF PULMONARY 
INFLAMMATION VIA PROTEIN LEVELS.
13. Remove the left lung with the attached trachea and cannula for inflation 
fixation of the lung in 4% paraformaldehyde. Turn the absorbent paper 180° 
and hold the cannula directly up with the non-dominant hand in a manner that 
does not cause the cannula to tear the trachea. Carefully and slowly cut the 
muscles/connective tissue attached to the trachea. Once the thoracic cavity is 
reached, be careful not to puncture the left lungs while cutting. Continue 
cutting connective tissue, the esophagus, and the aorta to free the left lung/
trachea/heart.
Use a small tugging motion on the canula while pulling directly up to 
visualize tissue that are attached to the trachea/left lung and require 
cutting. Use small incisions while keeping the scissors pointed 
downward at roughly a 45° angle.
14. The left lung is fixed using a tissue perfusion system. Fix the left lung lobe 
for 1 hour at 30cm hydrostatic pressure using 4% paraformaldehyde. After an 
hour, submerge the inflated lung in 4% paraformaldehyde in a 20mL 
scintillation vial and store at 4°C.
To process the left lung for histopathology, refer to section 
ASSESSMENT OF PULMONARY INFLAMMATION VIA 
HISTOPATHOLOGY.
15. Continue collecting other organs if other endpoints will be measured. Once 
completed, properly discard the carcasses in biohazard bags following all 
proper institutional procedures.
SUPPORT PROTOCOL 1
ASSESSMENT OF BRONCHO-ALVEOLAR LAVAGE FLUID FOR PULMONARY 
INFLAMMATORY CELLULAR PROFILES
A characteristic feature of mouse models of allergic asthma is the influx of inflammatory 
cells into the lung. Specifically, eosinophils are indicators of allergic responses. 
Additionally, there is also a large influx of monocytes and neutrophils into the airspace of 
the lungs when HDM allergen is administered. The profile of immune cells in the lung can 
indicate the extent and type of inflammatory response. To obtain and quantify white blood 
cells, the lungs are lavaged (generally in the same delivery vehicle used for allergen and PM) 
by cannulation of the animal trachea followed by instillation of the appropriate solution 
using a syringe and re-collection for microscopic analysis.
Materials—Centrifuge (refrigerated)
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Sterile saline, PBS, or HBSS
0.5mL microcentrifuge tubes
Trypan blue solution (0.4%)
20μL, 200μL, and 1000μL pipettes with appropriate tips
Hemocytometer
Light microscope
Shandon Cytospin 4 centrifuge
Shandon filter cards (for samples with <0.4mL volume)




Hematoxylin and eosin stain
Data sheet to count/calculate cells
1. Centrifuge the 5mL round bottom tubes containing BAL fluid at 500 × g 
for 15 min at 4°C.
2. Remove the supernatant and re-suspend the cell pellet in 0.5mL of the 
appropriate solvent (sterile saline, PBS, or HBSS). The supernatant may 
be aliquoted into microcentrifuge tubes, flash frozen in liquid nitrogen and 
stored at −80°C for further analysis of BAL (via Lowry Protein Assay 
and/or ELISA).
3. Trypan Blue Solution is used to check cellular viability; dead cells turn 
blue as a result of membrane permeability. In a 0.5mL microcentrifuge 
tube combine 10μL of Trypan Blue Solution and 100μL volume from the 
re-suspended cells. Gently vortex and incubate for 1 min at room 
temperature.
4. Gently vortex and add 10μL of the cell/trypan cell mixture into the 
hemocytometer counting chamber.
5. Using a light microscope, count the total number of viable cells (also 
count non-viable cells separately) in each of the 4 hemocytometer 
chamber quadrants (each quadrant has a length and width of 1mm and a 
depth of 0.1mm). Count cells that touch the upper and left perimeters and 
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exclude cells that touch the lower and right perimeters. Count only white 
blood cells. Do not count epithelial cells or red blood cells.
6. Use the following equation to calculate the total white blood cells 
recovered per mL of lavage fluid (cells/mL):
Where 104 is equivalent to the conversion factor from the volume 
of 1 quadrant of the hemocytometer (1mm × 1mm × 0.1mm = 
0.1mm3) to a volume of 1mL (0.1mm3=10−4cm3 since 
1cm3=1mL; therefore, 10−4cm3=104/mL)
The dilution factor of 1.1 represents the fraction of Trypan Blue 
Solution volume plus the volume of cell suspension, over the 
volume of cell suspension (10 μL of Trypan Blue Solution plus 
100 μL cell suspension, divided by 100 μL, corresponding to the 
volume of cell suspension alone, is equal to 1.1)
*The same equation can be used to determine the number non-
viable cells/mL (non-viable cells are counted separately from 
viable cells) as a measure of cell death/inflammation
7. Prepare each cytospin slide by using approximately 1.5 × 103 cells in a 
volume of 100μL. Dilute the cells if necessary in the appropriate solvent. 
Add the cell suspension to a single cytospin funnel attached to a glass 
slide containing absorbent paper. Centrifuge for 5 min at 1,500 rpm. It is 
recommended that slides be made in duplicate or triplicate for each 
animal.
8. Air dry the slides for 10 min and fix in 100% methanol for 10 sec. Air dry 
the slides in a fume hood.
The slides may be stored at this point for staining at a different 
time.
9. Stain the slides with hematoxylin and eosin as recommend by the 
manufacture’s protocol. Coverslip the slides.
10. Using a light microscope, count 500 white blood cells per slide. 
Differentiate between eosinophils, lymphocytes, macrophages and 
neutrophils. The data can be expressed as number of cells for each cell 
type or percent cell type.
SUPPORT PROTOCOL 2
ASSESSMENT OF PLASMA IgE
Immunoglobulin E is indicative of allergic responses. Both OVA and HDM allergens can 
stimulate class switching in B cells to produce allergen-specific IgE that can be detected in 
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the lung and systemically (in the blood). The detection of IgE can be used to assess the 
degree and the extent of the allergic response.
Materials—Centrifuge (refrigerated)
1.5mL microcentrifuge tubes
1000μL pipette with appropriate tips
Mouse IgE ELISA kit (various manufacturers)
1. To collect plasma, centrifuge the blood collected in ETDA-coated tubes at 
1000 × g for 10 min at 4°C, ideally within 30 min after blood collection.
2. Transfer the plasma (top aqueous layer) to newly labeled 1.5 mL 
microcentrifuge tubes and freeze at −80°C.
3. Using a commercially available IgE ELISA kit, follow the manufacturer’s 
instructions to determine IgE levels in blood plasma. A dilution of plasma 
is recommended, but will be dependent on the range of the ELISA kit; 
perform an optimization assay to calculate the optimal dilution ratio.
SUPPORT PROTOCOL 3
ASSESSMENT OF PULMONARY INFLAMMATION VIA HISTOPATHOLOGY
We recommend lung histopathological assessment to determine the overall level of 
pulmonary inflammation, specifically to investigate pathological changes produced by PM 
treatment. We refer the reader to Current Protocols in Molecular Biology, UNIT 14.1, 
Fixation, Embedding, and Sectioning of Tissues, Embryos, and Single Cells (Zeller, 1989).
1. Embed lung tissue following the protocol detailed in “Paraformaldehyde 
Fixation and Paraffin Wax Embedding of Tissues and Embryos” (Zeller, 
1989).
2. Section lung tissue following the protocol detailed in “Sectioning Samples 
in Wax Blocks” (Zeller, 2001).
3. Sectioned lung tissues can be assessed with various stains. We recommend 
the use of a hematoxylin and eosin (H&E) stain, a combined eosinophil 
and mast cell (CEM) stain, and an alcian blue periodic acid Schiff 
(ABPAS) stain.
Morphometric analysis may be used to quantify intraepithelial 
mucosubstance content as a method to characterize the allergic 
response. We refer the reader to (Carosino et al., 2015) for a 
description of the protocol.
4. Tissue sections may also be used to perform immunohistochemistry of 
proteins of interest.
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ASSESSMENT OF PULMONARY INFLAMMATION VIA GENE EXPRESSION
Inflammation can be rapidly assessed by isolating RNA for the generation of CDNA to 
perform quantitative PCR. A variety of genes can be tested, include those associated with 
immunological/inflammatory changes (chemokines and cytokines), phase I and II 
metabolism enzymes, and transcription factors. The advantage of this method is that a large 
number of genes can be assessed at a relatively lower cost compared to protein based 
techniques. Furthermore, nearly any gene can be assessed by generating the appropriate 
primers from the mRNA nucleotide sequence using the National Center for Biotechnology 
Information’s Nucleotide search engine. This allows the investigator to tailor their study to 
specific genes of interest. However, we note the limitation of this technique, in that changes 
in mRNA do not always reflect changes in protein levels, and therefore key genes that are 
studied by the investigator should further examined using protein detection based assays 
(ELISA or Western Blot). We refer the investigator to Sigma-Aldrich’s TRI Reagent® 
Protocol for the extraction RNA from lung tissue. Below, Steps 2-9, are an adaptation of the 
TRI Reagent® Protocol for this experiment.
Materials—1.5mL microcentrifuge tubes
2mL round bottom microcentrifuge tubes
20μL, 200μL, and 1000μL pipettes with appropriate tips
TRI Reagent® (Sigma-Aldrich)




RNA extraction kit (various manufactures)
Ultraviolet-visible light spectrophotometer (Nanodrop, Thermo Scientific)
Nuclease-free water
Reverse transcription PCR kit (various manufactures)
SYBR® Green Master Mix (Applied Biosystems™, Thermo Scientific)
Real-time PCR instrument (various manufactures)
Gene specific primers (species-specific)
RNA Isolation—
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1. Use only one of the right lung lobes. If lung tissue was frozen at −80°C, 
thaw cryovials on ice. Alternatively, if the lung tissue was stored in 
RNAlater Solution© (room temperature or 4°C) the tissue is ready to be 
processed.
If the lung tissue was not stored in a RNA preservative solution 
but rather flash frozen at −80°C, be prepared to immediately 
place the tissue in TRI Reagent® as soon as it thaws. Failure to 
do so will result in degradation of RNA material.
2. In a clean 2mL round bottom microcentrifuge tube, place a clean stainless 
steel bead and 1mL of TRI Reagent® (perform this step and subsequent 
steps involving TRI Reagent® in a fume hood as this reagent is toxic, 
please refer to the MSDS). Transfer the lung lobes into the appropriately 
labeled 2mL microcentrifuge tubes and ensure the tissue is completely 
submerged in the TRI Reagent®.
3. Place the microcentrifuge tubes in a TissueLyser and homogenize the lung 
tissue for 30 sec at a frequency of 27 Hz (1/s). Determine if the tissue is 
homogenized. This step may be repeated once or twice if the tissue is not 
completely homogenized. If repeated, wait 1 min between each 
homogenization step to prevent RNA degradation via excessive heat.
4. Incubate the homogenate for 5 min at room temperature. This step is 
important for the TRI Reagent® to deactivate RNases and dissociate RNA 
complexes.
5. After 5 min, transfer the entire 1mL homogenate lysate to a newly labeled 
1.5mL tube (in the fume hood). The aim of this step is to remove the bead 
from the solution without contaminating the solution.
6. Add 200μL of chloroform to each tube. Mix the tubes gently by inverting 
for 15 seconds. Incubate the samples for 3 min at room temperature.
7. Centrifuge the samples at 12,000 × g for 15 min at 4°C.
8. Label clean 1.5mL tubes and transfer 350μL of the top clear aqueous layer 
containing RNA from the centrifuged samples to the newly labeled tubes. 
Avoid contamination from the middle white layer (DNA) or the bottom 
pink organic layer (proteins & lipids).
9. Use a commercially available RNA extraction kit according to the 
manufacturer’s instructions to obtain RNA for gene analysis.
10. Once RNA is eluted with water, measure the RNA concentration of each 
sample using a spectrophotometer.
Always keep RNA on ice during all procedures. Store RNA at 
−20°C or −80°C to prevent degradation and avoid freeze-thaw 
cycles.
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Reverse Transcription PCR and Quantitative PCR—
11. Perform reverse transcription polymerase chain reaction (RT-PCR) of the 
RNA to generate stable complementary DNA (cDNA) using a commercially 
available RT-PCR kit according to the manufacturer’s instructions.
12. Once cDNA is obtained, use a SYBR® Green-based detection system to 
perform quantitative polymerase chain reaction (qPCR) according to the 
manufacturer’s instructions. Analyze Ct-values using the ΔΔ-Ct method to 
determine fold change of gene expression for genes of interest in treated 
animals vs. control animals that have been standardized to a housekeeping 
control gene.
SUPPORT PROTOCOL 5
ASSESSMENT OF PULMONARY INFLAMMATION VIA PROTEIN LEVELS
The assessment of specific proteins should be reserved for the study of key targets of 
interest. Gene changes that are found to be biologically significant to the allergic or 
toxicological response can be confirmed by assessing protein levels using assays such as 
ELISA or Western Blot.
Materials—2mL round bottom microcentrifuge tubes
Balance
20μL, 200μL, and 1000μL pipettes with appropriate tips
Tissue/cell lysis kit (various manufactures)
Lowry protein assay kit (various manufactures)
Spectrophotometer (to measure protein content)
Mouse enzyme-linked immunoabsorbant assay (ELISA) kit (various manufactures)
Data sheets for recording lung mass and dilution volumes
1. Use only one of the right lung lobes. Remove the cryovials from −80°C 
and thaw on ice.
2. Label 2mL round bottom microcentrifuge tubes and place the appropriate 
lung samples in each tube. Keep the tubes on ice during this procedure.
3. Homogenize the lung tissue using a tissue/cell lysis kit following the 
manufacture’s protocol. Aliquots should be made of lung homogenate and 
immediately frozen at −80°C for future experiments. Avoid freeze-thaw 
cycles. From this point forward, always keep the lung homogenate on ice 
during all future experiments.
4. Using the supernatant collected after homogenization, perform a Lowry 
protein assay to measure protein content using the manufacture’s protocol.
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5. Use the lung homogenate to perform the ELISA according to the 
manufacturer’s protocol on proteins of interest. Standardize the ELISA 
readout (ng/mL or pg/mL) to the total protein content per mL obtained in 
Step 4. Standardized values should be expressed as ng/mg or pg/mg.
Lung homogenate must be diluted to concentrations that fall 
within the protein standards for each ELISA assay. The dilution 
factor will depend on the sensitivity of the ELISA (standard 
range) as well as the content of specific proteins of interest in the 
lung sample. We suggest the user perform an optimization assay 
with various concentrations of the lung homogenate (1:1, 1:10, 
1:100, etc.) using a small sample size to determine the optimal 
lung homogenate dilution factor.
6. Lung homogenate can be used to perform other downstream applications, 
such as immunoprecipitation, western blots, electrophoretic motility shift 
assay, or other assays that assess protein activity.
COMMENTARY
Background Information
Much of the early work that studied the toxicology of PM found that certain components had 
the potential to produce free radicals, which through mechanisms, such as redox cycling and 
Fenton chemistry, would generate oxidative stress. The activation of oxidative stress 
pathways was, therefore, responsible for the observed biological effects, mainly cellular 
damage and inflammation. It is important to note that PM-mediated oxidative stress occurs 
exogenously, that is directly from components of the PM, as well as endogenously via 
activated macrophages that release reactive chemical species as a result of PM phagocytosis. 
This has been the most widely accepted hypothesis to explain the toxicity of PM. The 
toxicity of PM has been characterized into three general processes (or Tiers) that occur in a 
concerted fashion: 1) free radicals generate oxidative stress that leads to an upregulation of 
phase I and II enzymes for detoxification; 2) free radicals overwhelm detoxification 
processes and trigger inflammation via the activation of epithelial and immune cells that 
release of pro-inflammatory cytokines and chemokines; and 3) the failure to clear PM and 
long term exposure to PM leads to chronic inflammation that initiates disease or enhances 
ongoing disease states (Ayres et al., 2008).
With respect to allergy, and as demonstrated through our experimental animal model, 
oxidative stress may not be the sole explanation for the enhancement of inflammation seen 
in subsequent encounters with the allergen (challenge). The fact that PM is not administered 
in the challenge period in this model, yet heightened inflammatory responses are observed in 
animals exposed to PM during allergen sensitization suggest that specific components of PM 
may modulate immunological memory during the formation of the adaptive immune 
response. In recent years, polyaromatic hydrocarbons, components of fossil fuel and organic 
matter combustion, have gained attention for their ability to alter the adaptive immune 
response through the aryl hydrocarbon receptor (AhR). The AhR is a cytosolic receptor that 
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binds both endogenous and exogenous ligands. The AhR plays a pivotal role in T cell 
differentiation, with some ligands promoting regulatory T cell (Treg) differentiation and 
others ligands promoting Th17 differentiation. Kynurenine, a byproduct of tryptophan 
metabolism by the enzyme indoleamine 2,3-dioxygenase (IDO1) in dendritic cells promotes 
Treg differentiation in an AhR-dependent manner (Mezrich et al., 2010). Conversely, 
exogenous ligands, such polyaromatic hydrocarbons in air pollution, appear to act as 
“danger signals” that promote Th17 differentiation and inflammation through the AhR, as 
mice lacking the AhR fail to develop Th17 responses (van Voorhis et al., 2013). Although it 
is unclear how AhR ligands lead to differential biological outcomes, ligand binding strength, 
duration, and method of exposure are thought to dictate the delicate balance between Treg 
and Th17 differentiation. It is postulated that high levels of air pollution exposure impede 
bacterial clearance mechanisms in the lung (i.e., mucocillary apparatus and alveolar 
macrophage-mediated clearance), thereby enhancing susceptibility to infection. Th17 
responses are, therefore, heightened to recruit neutrophils into the lung via IL-17 and 
promote epithelial cell repair via IL-22 to mitigate these effects (Julliard et al., 2014). These 
findings support an alternative method through which PM may promote inflammation by 
modulating the immune system, independent of oxidative stress.
Critical Parameters and Troubleshooting
Allergen Preparation—HDM allergen contains high levels of endotoxin, which 
influences the allergic response, typically producing a more neutrophilic response. The 
allergen can be purified by using endotoxin-removal kits, such as Detoxi-Gel™ Endotoxin 
Removing Gel Columns (Thermo Scientific), that significantly reduce endotoxin levels, 
although protein is also lost. After purification, the amount of endotoxin in the allergen can 
be measured using a Limulus Amebocyte Lysate assay (Kinetic-QCL; Lonza), and the total 
protein content can be measured using a Lowry assay. It is important to use endotoxin free 
pipette tips, glassware, and plastic ware; glass can be treated overnight at 175°C to destroy 
endotoxin and plastic ware can be submerged in 1M NaOH overnight to destroy endotoxin.
Allergen and Particulate Matter Administration—During the intranasal 
administration, the mouse may temporarily halt its breathing pattern, preventing the dose 
from being inhaled. Three techniques can be used to ensure the entire dose is inhaled: 1) 
temporarily stop drop-wise dosing until the animal begins breathing again; 2) gently 
massage the chest of the mouse using the thumb to expand/compress the thoracic cavity to 
assist inhalation; or 3) if the mouse begins to regain consciousness, place it back in the 
anesthetic chamber for 1-2 min.
Anticipated Results
Total cells recovered by BAL should be elevated in allergen and allergen+PM groups 
compared to PBS and PM controls. A comparison between allergen and allergen+PM groups 
can give a general indication of overall inflammatory potential of PM. As stated previously, 
not all types of PM can enhance allergic inflammation. Alternatively, no changes between 
the allergen and allergen+PM groups does not necessarily imply PM does not have 
inflammatory effects, as these effects can occur at sub-cellular levels that may not result in 
significant influx of leukocytes into the lung. The frequency of cell types found in the lung, 
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from most to least common, in allergen±PM treated mice is: monocytes, macrophages, 
neutrophils, eosinophils, and lymphocytes. The lungs of PBS and PM control mice typically 
are composed entirely of macrophages (~90%). PM treated mice do not exhibit an 
inflammatory profile because PM is administered 12 days prior to the analysis and PM by 
itself, at the dose administered, does not produce significant inflammatory effects relative to 
allergen treatment.
Histopathological analysis of the lung is done to determine the anatomical locations of 
inflammation. We note here that performing a whole-lung lavage may significantly alter the 
location of leukocytes and focal points of inflammation that occur in-vivo. Therefore, we 
recommend the use of split lung lavage, as noted in the protocol. The HDM-allergic mouse 
model exhibits marked to severe sub-epithelial inflammation due to an influx of 
predominantly monocytes, neutrophils and eosinophils. Inflammatory cells are also elevated 
in perivascular regions with occasional focal points of inflammation commonly seen in the 
parenchyma. HDM allergen also elicits significant intra-epithelial mucosubstance 
production in the airways, a feature that is absent in an OVA allergy model if the allergen is 
administered intranasally during sensitization (in contrast to i.p. delivery).
Gene expression of inflammatory cytokines that drive allergic reactions are elevated, 
particularly in the allergen+PM group. These include the following cytokines: IL-4, IL-5, 
IL-6, IL-13, IL-25, and IL-33. Other genes of interest that investigators may wish to examine 
include oxidative stress enzymes, chemokines, and genes involved in AhR signaling. Protein 
levels of elevated genes can be confirmed via ELISA.
Further measurements can be performed to characterize the immunotoxicological effects of 
PM on the allergic response in this mouse model of asthma. For example, quantifying the 
ratio of reduced to oxidized glutathione (GSH/GSSG) or performing a DTT assay can 
provide insights into the oxidative potential of PM. Gas chromatography-mass spectrometry 
can also be used to quantify polyaromatic hydrocarbon content in collected atmospheric PM. 
Plasma samples can be further assessed for other antibody responses, such as IgG4. BAL 
fluid can be further examined for protein content (Lowry protein assay), specific proteins 
(ELISA) or evidence of cellular injury (lactate dehydrogenase). Phenotyping of immune 
cells via flow cytometry can be a powerful tool to meticulously characterize in-vivo 
mechanisms. In-vivo lung-derived immune cells may also be cultured to further delineate 
mechanisms by re-challenging cells with allergen and characterizing their responses. Lastly, 
measurements in lung function can be performed to determine airway hyperresponsiveness, 
including the use of methylcholine challenge.
Time Considerations
Mice should be ordered with sufficient time to allow at least a one week acclimation period 
after delivery. The dosing schedule of the mice will take 2 weeks: sensitization on days 1, 3, 
and 5; challenge on days 12-14; and tissue collection performed on day 15. On day 15, 
lavage and lung tissue collection for each mouse will take approximately 15-20 min, and 
perfusion fixation of the lung tissue will take 1 hour per lung. Total BAL cell counts, 
cytospin slide preparation, and staining can be completed by the end of day 15. The time to 
complete the necropsy and tissue collection on day 15 will depend on the number of animals 
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as well as the size and efficiency of the staff. Large sample-size experiments may be split 
into multiple day necropsies; however, the dosing schedule for the mice will need to be 
altered respectively.
Preparation of lung tissue sections from paraformaldehyde fixed tissue will take 
approximately one week. Fixation of the lung tissue in 4% paraformaldehyde is done on day 
15 of the protocol. The following day, the fixation solution is replaced with ethanol for tissue 
dehydration for 24 hours. Allot two days for paraffin embedding of tissue followed by 1 day 
for sectioning of tissue (depending on number of samples). The sectioned lung tissue can 
then be stained with various histological stains or can be used for immunohistochemistry, 
which can be performed in a single day.
BAL differential cell count analysis (500 cells/slide) will take an experienced counter 15-20 
minutes to count each slide. Histopathological assessment of the lung will depend on the 
analysis performed and the number of slides to be analyzed. Semi-quantitative 
histopathological analysis and intra-epithelial mucosubstance quantification can be time-
intensive techniques.
To perform gene expression analysis allow one day for complete trizol extraction of RNA, 
RNA purification, and RNA concentration measurements. Conversation of RNA to cDNA 
via RT-PCR can be completed the following day as well as a qPCR reaction. The number of 
days to perform subsequent qPCR reactions will depend on the battery of genes being tested.
When performing protein analysis of the total lung, schedule two days to perform lung 
homogenization. On day one, the lungs are homogenized and frozen over night to promote 
cell membrane fracture. On day two, the lung homogenate is thawed and the supernatant is 
collected after centrifugation. A Lowry protein assay is then used to quantify total lung 
protein to standardize downstream assay values. The samples can then be processed using 
protein analysis assays, such as immunostaining (ELISA) or immunoblot (western blot), 
each of which may take 2-3 days per each protein of interest analyzed.
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The protocol is designed to allow investigators to assess the immunotoxicological 
mechanisms of particulate matter, a component of air pollution, during development of 
the immune response in the context of a mouse model of allergic airway inflammation. 
Using an acute exposure model of 14 days, mice are sensitized with allergen and PM and 
challenged with allergen only to determine how PM modulates the development of the 
adaptive immune response and subsequent allergic inflammatory response after allergen 
challenge. The unique aspect of this protocol is that it can be adapted to study how 
various characteristics of air pollution, such as PM size, PM source, or chemical 
composition, shape the allergic response in a mouse model of asthma.
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Illustration of how to position the suture behind the trachea, create an incision and cannulate 
the trachea.
Castañeda and Pinkerton Page 24














Depiction of securing the right lung by using a suture to tie the primary right bronchus. Use 
tweezers to carefully guide the suture behind the lungs and heart. Tie the suture tightly 
around the right bronchus. H= heart, LL= left lung, RL= right lung, T= thymus.
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